IntraCellular Therapies (ITCI)
(Delayed Data from NSDQ)
$73.26 USD
+1.13 (1.57%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $73.35 +0.09 (0.12%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Earnings News For ITCI
-
Will Intra-Cellular Therapies (ITCI) Report Negative Q1 Earnings? What You Should Know
-
Intra-Cellular (ITCI) Q4 Loss Narrower Than Expected, Sales Miss
-
Intra-Cellular: Q4 Earnings Snapshot
-
Intra-Cellular Therapies Reports Fourth Quarter And Full-Year 2023 Financial Results And Provides Corporate Update
-
Intra-Cellular Therapies (ITCI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
-
Intra-Cellular (ITCI) Q3 Earnings Top, Product Sales View Raised
-
Intra-Cellular: Q3 Earnings Snapshot
-
Intra-Cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance
-
Intra-Cellular Therapies (ITCI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
-
Intra-Cellular (ITCI) Q2 Earnings & Sales Top, '23 View Raised
-
Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates
-
Intra-Cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance
-
Intra-Cellular (ITCI) Q1 Earnings Top, Caplyta Volume Rises
-
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Tops Revenue Estimates
-
Intra-Cellular: Q1 Earnings Snapshot
-
Intra-Cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update
-
Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy?
-
Intra-Cellular (ITCI) Up 20.5% Since Last Earnings Report: Can It Continue?
-
Intra-Cellular (ITCI) Q4 Earnings & Sales Top, Caplyta Shines
-
Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates
-
Intra-Cellular: Q4 Earnings Snapshot
-
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
-
Will Intra-Cellular Therapies (ITCI) Report Negative Earnings Next Week? What You Should Know
-
Intra-Cellular (ITCI) Beat on Q3 Earnings and Sales Estimates
-
Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates